Valuation: Annexon, Inc.

Market Cap 760M 681M 628M 568M 1.06B 72.39B 1.08B 7.49B 2.99B 37.89B 2.85B 2.79B 120B P/E 2026 *
-3.84x
P/E 2027 * -4.11x
Enterprise Value 682M 611M 563M 510M 953M 64.92B 969M 6.72B 2.68B 33.97B 2.56B 2.5B 108B EV / Sales 2026 *
-
EV / Sales 2027 * 19.7x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week+5.25%
Current month-5.20%
1 month-2.91%
3 months-17.49%
6 months-31.92%
Current year-20.12%
1 week 3.66
Extreme 3.66
4.2
1 month 3.36
Extreme 3.355
4.38
Current year 3.36
Extreme 3.355
7.18
1 year 2.54
Extreme 2.54
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
18.06
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 67 05/02/2021
Director/Board Member 56 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
24/9/26 Buy

Chief Executive Officer

26,065 0.0137%
10/8/26 Free

Director

175,000 0.0923%
28/5/26
Alerce Investment Management LP
BuyCompany 613,497 0.3775%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%+5.25%+25.71%+92.79% 760M
+0.34%+1.12%+34.75%+61.06% 64.38B
-0.17%+2.66%+14.32%+83.58% 56.16B
+1.08%+2.50%+15.97%+107.90% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
+0.82%+44.36%+107.50%+91.71% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.13%+4.58%+50.46%+156.36% 39.34B
Weighted average by Cap. +0.02%+3.60%+50.13%+162.20%

Financials

2026 *2027 *
Net sales - 35.32M 31.64M 29.19M 26.41M 49.39M 3.36B 50.19M 348M 139M 1.76B 133M 130M 5.58B
Net income -213M -191M -176M -159M -298M -20.29B -303M -2.1B -838M -10.62B -800M -783M -33.64B -216M -193M -178M -162M -302M -20.57B -307M -2.13B -850M -10.76B -811M -793M -34.09B
Net Debt -78.52M -70.33M -64.88M -58.71M -110M -7.48B -112M -774M -309M -3.91B -295M -288M -12.39B -63.35M -56.74M -52.35M -47.37M -88.58M -6.03B -90.01M -625M -249M -3.16B -238M -233M -10B
Projected Income Statement - Annual - Annexon, Inc.
Logo Annexon, Inc.
Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis.
Employees
92
Date Price Change Volume
29/10/26 US$4.010 -0.74% 3,284,984
28/10/26 US$4.040 +7.45% 4,011,589
27/10/26 US$3.760 +1.62% 2,964,506
26/10/26 US$3.700 -1.33% 2,648,826
23/10/26 US$3.750 -1.57% 2,575,607
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Annexon, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.010USD
Average target price
17.00USD
Spread / Average Target
+323.94%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Annexon, Inc.
  1. Stock Market
  2. Stocks
  3. ANNX Stock